ATXS vs. SLDB, NEOS, ICCC, FRLN, CORV, ZLAB, CPRX, ARVN, KROS, and NAMS
Should you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Solid Biosciences (SLDB), Neos Therapeutics (NEOS), ImmuCell (ICCC), Freeline Therapeutics (FRLN), Correvio Pharma (CORV), Zai Lab (ZLAB), Catalyst Pharmaceuticals (CPRX), Arvinas (ARVN), Keros Therapeutics (KROS), and NewAmsterdam Pharma (NAMS). These companies are all part of the "medical" sector.
Solid Biosciences (NASDAQ:SLDB) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.
Solid Biosciences' return on equity of -53.14% beat Astria Therapeutics' return on equity.
Astria Therapeutics received 302 more outperform votes than Solid Biosciences when rated by MarketBeat users. Likewise, 72.58% of users gave Astria Therapeutics an outperform vote while only 67.55% of users gave Solid Biosciences an outperform vote.
Astria Therapeutics has lower revenue, but higher earnings than Solid Biosciences. Astria Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.
Solid Biosciences has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
In the previous week, Solid Biosciences had 2 more articles in the media than Astria Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Astria Therapeutics. Solid Biosciences' average media sentiment score of 0.93 beat Astria Therapeutics' score of 0.81 indicating that Astria Therapeutics is being referred to more favorably in the news media.
Solid Biosciences currently has a consensus price target of $16.00, suggesting a potential upside of 106.19%. Astria Therapeutics has a consensus price target of $22.50, suggesting a potential upside of 148.34%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Astria Therapeutics is more favorable than Solid Biosciences.
81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are held by institutional investors. 13.6% of Solid Biosciences shares are held by company insiders. Comparatively, 2.9% of Astria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Astria Therapeutics beats Solid Biosciences on 10 of the 16 factors compared between the two stocks.
Get Astria Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Astria Therapeutics Competitors List
Related Companies and Tools
